Small molecule antagonists of the tachykinin NK2 receptor

被引：5

作者：

Fattori, D ^{[1
]}

Altamura, M ^{[1
]}

Maggi, CA ^{[1
]}

机构：

[1] Menarini Ric SpA, Dept Chem, I-00040 Rome, Italy

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2004年 / 4卷 / 03期

关键词：

NK2 receptor antagonists;

D O I：

10.2174/1389557043487376

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The NK2 receptor (member of the tachykinin receptor family) is mainly located in the smooth muscle of the urinary, respiratory and gastrointestinal tracts, with limited presence in the CNS. This has raised interest in tachykinin NK2 receptor antagonists for the treatment of urological disorders, asthma. This review outlines progress done after 1998 in the field of NK2 small molecule antagonists, both acting on the NK1/NK2, NK2/NK3, NK1/NK2/NK3 receptors and selective for the NK2 one.

引用

页码：331 / 340

页数：10

共 55 条

[1] The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough [J].

Advenier, C ;

Lagente, V ;

Boichot, E .

EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (08) :1892-1906

[2]

AHARONY D, 1998, EUR RESP J S29, V12

[3] Design, synthesis, and SAR of tachykinin antagonists:: Modulation of balance in NK1/NK2 receptor antagonist activity [J].

Albert, JS ;

Aharony, D ;

Andisik, D ;

Barthlow, H ;

Bernstein, PR ;

Bialecki, RA ;

Dedinas, R ;

Dembofsky, BT ;

Hill, D ;

Kirkland, K ;

Koether, GM ;

Kosmider, BJ ;

Ohnmacht, C ;

Palmer, W ;

Potts, W ;

Rumsey, W ;

Shen, LH ;

Shenvi, A ;

Sherwood, S ;

Warwick, PJ ;

Russell, K .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3972-3983

[4] Successful bridging from a peptide to a non peptide antagonist at the human tachykinin NK-2 receptor [J].

Altamura, M ;

Canfarini, F ;

Catalioto, RM ;

Guidi, A ;

Pasqui, F ;

Renzetti, AR ;

Triolo, A ;

Maggi, CA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) :2945-2948

[5] SCH 206272:: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist [J].

Anthes, JC ;

Chapman, RW ;

Richard, C ;

Eckel, S ;

Corboz, M ;

Hey, JA ;

Fernandez, X ;

Greenfeder, S ;

McLeod, R ;

Sehring, S ;

Rizzo, C ;

Crawley, Y ;

Shih, NY ;

Piwinski, J ;

Reichard, G ;

Ting, P ;

Carruthers, N ;

Cuss, FM ;

Billah, M ;

Kreutner, W ;

Egan, RW .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (02) :191-202

[6] The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671 [J].

Beaumont, K ;

Harper, A ;

Smith, DA ;

Bennett, J .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 12 (01) :41-50

[7] Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human [J].

Beaumont, K ;

Harper, A ;

Smith, DA ;

Abel, S .

XENOBIOTICA, 2000, 30 (06) :627-642

[8] Expression of tachykinin NK2 receptor mRNA in human brain [J].

Bensaid, M ;

Faucheux, BA ;

Hirsch, E ;

Agid, Y ;

Soubrié, P ;

Oury-Donat, F .

NEUROSCIENCE LETTERS, 2001, 303 (01) :25-28

[9] Discovery of novel, orally active dual NK1/NK2 antagonists [J].

Bernstein, PR ;

Aharony, D ;

Albert, JS ;

Andisik, D ;

Barthlow, HG ;

Bialecki, R ;

Davenport, T ;

Dedinas, RF ;

Dembofsky, BT ;

Koether, G ;

Kosmider, BJ ;

Kirkland, K ;

Ohnmacht, CJ ;

Potts, W ;

Rumsey, WL ;

Shen, LH ;

Shenvi, A ;

Sherwood, S ;

Stollman, D ;

Russell, K .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (20) :2769-2773

[10]

BHOGAL N, 1994, J BIOL CHEM, V269, P27269

← 1 2 3 4 5 6 →